Navigation Links
Mylan's Matrix First-to-File on Generic Version of Vfend(R) Antifungal
Date:10/29/2008

rest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
2. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
3. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
4. New: Longevinex(R) First to Introduce Micronized Resveratrol Matrix - Now Stabilized by Microencapsulation
5. Matrix registry probes adherence to clopidogrel at 1 year
6. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
7. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
8. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
10. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
11. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... cell disease, a condition characterized by deformed and ... most common genetic blood disorders affecting millions of ... Americans.(1) Research presented today at the 51st Annual ... intriguing studies on the acute danger that the ... disorder, evaluations of both new and standard treatments ...
(Date:12/6/2009)... Internet Sleep Disorders information and Treatment site ... sleep problems with herbal or natural sleep aids ... ,insomnia remedies for a good cause. The submissions ... Natural Sleep Aids ,Encyclopedia, by YOU, to be ... The site will donate 100% of the proceeds ...
(Date:12/5/2009)... combination has shown in a phase 1/2 clinical ... the treatment of patients newly diagnosed with multiple myeloma, ... say researchers from Dana-Farber Cancer Institute. , Partial responses ... patients treated with the drug combination in the multi-center ... response rate" in the phase 2 population, reports Paul ...
(Date:12/5/2009)... South Africa, December 5 The first Football,for ... Cape Town opened its doors,today (5 December 2009). ... Cape Premier Helen Zille, 2010 FIFA World Cup ... African Football Association,President Kirsten Nematandani and Executive Mayor ...
(Date:12/5/2009)... , , SATURDAY, Dec. 5 (HealthDay News) -- They,re not ... bad reactions to certain holiday traditions and need to ... to the American College of Allergy, Asthma and Immunology ... may choose to decorate with artificial plants, but both ...
Breaking Medicine News(10 mins):Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Keep Asthma, Allergies at Bay for the Holidays 2
... WEDNESDAY, Nov. 14 (HealthDay News) -- A protein that may ... to be a biomarker that indicates severe asthma. And it ... according to new research. , Reporting in the Nov. 15 ... Yale University researchers said that people with severe asthma were ...
... 34 years shows parental history, overweight are markers for ... The development of type 2 diabetes in adults can ... that,s followed a group of 814 children and adults ... Center found that parental history of diabetes, as well ...
... Community Hospital of Long Beach (CHLB) is entering to win a ... The hospital that receives the most votes will win the ... taking place NOW through December 31, ... ,Community Hospital of Long Beach, from the drop ...
... prepared testimony of NCPA president Steve Giroux before the ... the counter,availability of certain drugs., "Hello, I am ... and a pharmacist from Middleport, New York., NCPA ... public meeting to,explore the public health benefit of certain ...
... Plastic Surgery Procedures, LAS VEGAS, Nov. 14 ... raised questions about the safety of plastic,surgery. The factors ... concerns over her physician,s lack of board certification and,his ... should,be reassured that Donda West,s tragic outcome is unusual," ...
... donors share in success, Governor Phil Bredesen ... Consortium headquarters, Chili,s Care Center culmination of ... care, MEMPHIS, Tenn., Nov. 14 St. ... celebrated the national,grand opening of the Chili,s Care ...
Other Medicine News:Health News:Defensive Protein Linked to Asthma 2Health News:Defensive Protein Linked to Asthma 3Health News:Adult Type 2 Diabetes Can Be Predicted in Childhood 2Health News:Community Hospital of Long Beach - Help Us Win an MRI Scanner! 2Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 2Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 3Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 4Health News:NCPA President Steve Giroux's Testimony at FDA Behind the Counter Hearing 5Health News:Guide to Minimizing Your Plastic Surgery Risks 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 4
(Date:12/4/2009)... AstraZeneca (NYSE: AZN ) today announced ... approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets ... Major Depressive Disorder (MDD). SEROQUEL XR is the only ... treat both major depressive disorder as adjunctive therapy and ...
(Date:12/3/2009)... YORK, Dec. 3 Guidepoint Global, LLC , a ... Sleep Apnea Tracker, a monthly longitudinal data release that monitors ... Apnea market. ,, The Sleep Apnea Tracker captures actual ... in the United States from 15 different equipment providers going ...
(Date:12/3/2009)... ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. ... the signing of an agreement to provide extended ... next-generation sequencing projects performed at Ambry. ... Kammesheidt PhD, Ambry,s CSO said, "Our team at ...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 1Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 2Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 3Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 4Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 5Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 6Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 7Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 8Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 9Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 10Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 11Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 12Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 13Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 14Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 15Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 16Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 17Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 18Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of 240 46 3B Adjusted EPS 240 61 3B Company Raises 2009 Outlook 53036 19Sanofi aventis Announces Second Quarter 2009 Results 13244 1Sanofi aventis Announces Second Quarter 2009 Results 13244 2Sanofi aventis Announces Second Quarter 2009 Results 13244 3Sanofi aventis Announces Second Quarter 2009 Results 13244 4Sanofi aventis Announces Second Quarter 2009 Results 13244 5Sanofi aventis Announces Second Quarter 2009 Results 13244 6Sanofi aventis Announces Second Quarter 2009 Results 13244 7Sanofi aventis Announces Second Quarter 2009 Results 13244 8Sanofi aventis Announces Second Quarter 2009 Results 13244 9Sanofi aventis Announces Second Quarter 2009 Results 13244 10Sanofi aventis Announces Second Quarter 2009 Results 13244 11Sanofi aventis Announces Second Quarter 2009 Results 13244 12Sanofi aventis Announces Second Quarter 2009 Results 13244 13Sanofi aventis Announces Second Quarter 2009 Results 13244 14Sanofi aventis Announces Second Quarter 2009 Results 13244 15Sanofi aventis Announces Second Quarter 2009 Results 13244 16Sanofi aventis Announces Second Quarter 2009 Results 13244 17Sanofi aventis Announces Second Quarter 2009 Results 13244 18Sanofi aventis Announces Second Quarter 2009 Results 13244 19Sanofi aventis Announces Second Quarter 2009 Results 13244 20Sanofi aventis Announces Second Quarter 2009 Results 13244 21Sanofi aventis Announces Second Quarter 2009 Results 13244 22Sanofi aventis Announces Second Quarter 2009 Results 13244 23Sanofi aventis Announces Second Quarter 2009 Results 13244 24Sanofi aventis Announces Second Quarter 2009 Results 13244 25Sanofi aventis Announces Second Quarter 2009 Results 13244 26Sanofi aventis Announces Second Quarter 2009 Results 13244 27Narconon Graduate Delivers Drug Education in Florida 53033 1Narconon Graduate Delivers Drug Education in Florida 53033 2
... Pa. and LYON, France, Aug. 1 Sanofi,Pasteur, ... vaccine (Fluzone(R), Influenza Virus Vaccine) in the United,States ... doses of influenza,vaccine began shipping this week following ... Food and Drug Administration (FDA) on,July 14, 2008., ...
... CLL Meets ... Primary Endpoint, COPENHAGEN, ... GSK) announced today positive top-line,results from an interim analysis of the ... chronic lymphocytic,leukemia (CLL) patients with high unmet medical need. At the ...
Other Medicine Technology:Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 2Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 3Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 4Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US 5Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 2Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 3Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 4Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 5Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study 6
... The RapidPCP test is an ... test. It is,designed for qualitative determination ... above,a cut-off level of 25 ng/mL. ... in the point of care location,and ...
The RapidMTD test is an immunochromatography based one step in vitro test. It is,designed for qualitative determination of methadone in human urine specimens above a,cut-off level of 300 ng/mL. The a...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Medicine Products: